Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Seppi

Showing results (21-30 of 356) with videos related to

Pageof 36
Sort By:
Cerebellum (London, England)|May 17, 2022
Symptomatic Care in Multiple System Atrophy: State of the ArtAnna Grossauer, Victoria Sidoroff, Beatrice Heim, et al.
International Clinical Psychopharmacology|May 9, 2013
Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's diseaseMonika Edlinger, Klaus Seppi, Wolfgang Fleischhacker, et al.
Journal of Alzheimer'S Disease : JAD|November 26, 2002
Lewy bodies in patients presenting clinically with Alzheimer diseaseKurt A Jellinger, Klaus Seppi, Gregor K Wenning
Movement Disorders : Official Journal of the Movement Disorder Society|February 3, 2017
Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's diseasePhilipp Mahlknecht, Florian Krismer, Werner Poewe, et al.
Parkinsonism & Related Disorders|March 2, 2024
Longitudinal brain changes in Parkinson's disease with severe olfactory deficitKazuya Kawabata, Epifanio Bagarinao, Klaus Seppi, et al.
Archives of Neurology|March 14, 2003
Neuropathologic changes in Parkinson disease with late onset of dementiaKurt A Jellinger, Klaus Seppi, Gregor K Wenning
Neuropharmacology|April 17, 2020
New hopes for disease modification in Parkinson's DiseaseWerner Poewe, Klaus Seppi, Kathrin Marini, et al.
Neuro-Degenerative Diseases|October 16, 2007
Predictors of survival in dementia with lewy bodies and Parkinson dementiaKurt A Jellinger, Gregor K Wenning, Klaus Seppi
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
Grading of neuropathology in multiple system atrophy: proposal for a novel scaleKurt A Jellinger, Klaus Seppi, Gregor K Wenning
CNS Drugs|September 2, 2019
Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New FormulationsFederico Carbone, Atbin Djamshidian, Klaus Seppi, et al.
Pageof 36

Showing results (21-30 of 356) with videos related to

Sort By:
Pageof 36
Cerebellum (London, England)|May 17, 2022
Symptomatic Care in Multiple System Atrophy: State of the ArtAnna Grossauer, Victoria Sidoroff, Beatrice Heim, et al.
International Clinical Psychopharmacology|May 9, 2013
Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's diseaseMonika Edlinger, Klaus Seppi, Wolfgang Fleischhacker, et al.
Journal of Alzheimer'S Disease : JAD|November 26, 2002
Lewy bodies in patients presenting clinically with Alzheimer diseaseKurt A Jellinger, Klaus Seppi, Gregor K Wenning
Movement Disorders : Official Journal of the Movement Disorder Society|February 3, 2017
Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's diseasePhilipp Mahlknecht, Florian Krismer, Werner Poewe, et al.
Parkinsonism & Related Disorders|March 2, 2024
Longitudinal brain changes in Parkinson's disease with severe olfactory deficitKazuya Kawabata, Epifanio Bagarinao, Klaus Seppi, et al.
Archives of Neurology|March 14, 2003
Neuropathologic changes in Parkinson disease with late onset of dementiaKurt A Jellinger, Klaus Seppi, Gregor K Wenning
Neuropharmacology|April 17, 2020
New hopes for disease modification in Parkinson's DiseaseWerner Poewe, Klaus Seppi, Kathrin Marini, et al.
Neuro-Degenerative Diseases|October 16, 2007
Predictors of survival in dementia with lewy bodies and Parkinson dementiaKurt A Jellinger, Gregor K Wenning, Klaus Seppi
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
Grading of neuropathology in multiple system atrophy: proposal for a novel scaleKurt A Jellinger, Klaus Seppi, Gregor K Wenning
CNS Drugs|September 2, 2019
Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New FormulationsFederico Carbone, Atbin Djamshidian, Klaus Seppi, et al.
Pageof 36